{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:04:47Z","timestamp":1789625087135,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Talquetamab, a bispecific antibody, has a high efficacy in multiple myeloma (MM), with common dermatologic adverse events. We aim to describe the real\u2010world burden of cutaneous toxicities. A retrospective study of MM patients treated with talquetamab between March 2021 and February 2026. Demographic and clinical data were extracted from electronic health records. Cutaneous, nail, and mucosal toxicities attributed to talquetamab were recorded. Of 32 patients (mean age 61.4\u2009years; 59.4% male), 28 (87.5%) developed cutaneous adverse events. A total of 87 dermatologic events were recorded. Most frequent manifestations were exanthema (37.5% of cutaneous events), xerosis (33.3%), and palmoplantar involvement (46.9% of patients). Nail toxicity affected 75% of the cohort, predominantly onychomadesis. Mucositis affected 34.4%, with a tendency to occur earlier compared with cutaneous and nail toxicities. Dermatologic evaluation was associated with therapeutic management of adverse events (95.8% vs. 69.9%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0098). No patient required permanent talquetamab discontinuation due to mucocutaneous toxicity. Median time to resolution was 50\u2009days. Talquetamab is associated with a high burden of mucocutaneous toxicity. Early dermatologic assessment enables accurate diagnosis and effective management. These findings expand the clinicopathological spectrum of talquetamab toxicity and highlight the importance of interdisciplinary care.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.70497","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:53:26Z","timestamp":1789624406000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous Toxicities of Anti\u2010\n                    <scp>GPRC<\/scp>\n                    5\n                    <scp>D<\/scp>\n                    Bispecific Antibodies for Multiple Myeloma: Retrospective Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9063-8554","authenticated-orcid":false,"given":"Alfonso","family":"Gotor\u2010Rivera","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital \u201c12 de Octubre\u201d  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7637-7283","authenticated-orcid":false,"given":"Alberto","family":"Blanco\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital \u201c12 de Octubre\u201d  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Rodr\u00edguez\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital \u201cGregorio Mara\u00f1\u00f3n\u201d  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mart\u00ednez\u2010L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital \u201c12 de Octubre\u201d  Madrid Spain"},{"name":"Faculty of Medicine Complutense University of Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo L.","family":"Ortiz\u2010Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital \u201c12 de Octubre\u201d  Madrid Spain"},{"name":"Faculty of Medicine Complutense University of Madrid  Madrid Spain"},{"name":"Grupo de Oncolog\u00eda Cut\u00e1nea Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12)  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-3396","authenticated-orcid":false,"given":"F\u00e1tima","family":"Tous\u2010Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital \u201c12 de Octubre\u201d  Madrid Spain"},{"name":"Faculty of Medicine Complutense University of Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-024-01611-z","article-title":"Targeting GPRC5D for Multiple Myeloma Therapy","volume":"17","author":"Zhou D.","year":"2024","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T\u2010Cell\u2010Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari A.","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1159\/000538047","article-title":"Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma","volume":"147","author":"Heini A. D.","year":"2024","journal-title":"Acta Haematologica"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CMAR.S441550","article-title":"Perspectives on Talquetamab and Its Utility in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy","volume":"17","author":"Miller K. C.","year":"2025","journal-title":"Cancer Management and Research"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.23736\/S2784-8671.25.08222-2","article-title":"Dermatological Safety of Humanized Bispecific Antibody Talquetamab: Skin and Nail Adverse Events Related to a Novel Immunotherapy for Multiple Myeloma","volume":"160","author":"Scarf\u00ec F.","year":"2025","journal-title":"Italian Journal of Dermatology and Venereology"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2023.08.094","article-title":"Dermatological Toxicities Induced by T\u2010Cell\u2010Redirecting G Protein\u2010Coupled Receptor Family C Class 5 Member D Bispecific Antibody Talquetamab","volume":"90","author":"Lery M.","year":"2024","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/ddg.15502","article-title":"Dermatological Toxicities of Talquetamab, a New Bispecific Antibody: Case Series and Literature Review","volume":"22","author":"Mansilla\u2010Polo M.","year":"2024","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00520-023-08233-0","article-title":"Characterization of Dysgeusia and Xerostomia in Patients With Multiple Myeloma Treated With the T\u2010Cell Redirecting GPRC5D Bispecific Antibody Talquetamab","volume":"32","author":"Laheij A. M. G. A.","year":"2023","journal-title":"Supportive Care in Cancer"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2024-260751","article-title":"Dermatological Adverse Events Linked to Talquetamab Immunotherapy in Multiple Myeloma","volume":"17","author":"Zayad A.","year":"2024","journal-title":"BML Case Reports"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jdcr.2022.11.013","article-title":"Onychomadesis and Palmoplantar Keratoderma Associated With Talquetamab Therapy for Relapsed and Refractory Multiple Myeloma","volume":"31","author":"Narayan N.","year":"2022","journal-title":"JAAD Case Reports"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"828","DOI":"10.36849\/jdd.7170","article-title":"Talquetamab\u2010Induced Grover's Disease","volume":"22","author":"Kresch M.","year":"2023","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of Toxicities Associated With BCMA, GPRC5D, and FcRH5\u2010Targeting Bispecific Antibodies in Multiple Myeloma","volume":"19","author":"Pan D.","year":"2024","journal-title":"Current Hematologic Malignancy Reports"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.2024026622","article-title":"Genetic and Epigenetic Mechanisms of GPRC5D Loss After Anti\u2010GPRC5D CAR T\u2010Cell Therapy in Multiple Myeloma","volume":"146","author":"Ma S.","year":"2025","journal-title":"Blood"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous Adverse Effects With HER1\/EGFR\u2010Targeted Agents: Is There a Silver Lining?","volume":"23","author":"Per\u00e9z\u2010Soler R.","year":"2005","journal-title":"Journal of Clinical Oncology"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.70497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.70497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:53:28Z","timestamp":1789624408000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.70497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":14,"alternative-id":["10.1111\/1346-8138.70497"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.70497","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"2026-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1346-8138.70497"}}